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BACKGROUND AND PURPOSE
Glucagon-like peptide-1 (GLP-1) is secreted from enteroendocrine L-cells after food intake. Increasing GLP-1 signalling either
through inhibition of the GLP-1 degrading enzyme dipeptidyl-peptidase IV or injection of GLP-1-mimetics has recently been
successfully introduced for the treatment of type 2 diabetes. Boosting secretion from the L-cell has so far not been exploited,
due to our incomplete understanding of L-cell physiology. Elevation of cyclic adenosine monophosphate (cAMP) has been
shown to be a strong stimulus for GLP-1 secretion and here we investigate the activities of adenylate cyclase (AC) and
phosphodiesterase (PDE) isozymes likely to shape cAMP responses in L-cells.
EXPERIMENTAL APPROACH
Expression of AC and PDE isoforms was quantiﬁed by RT-PCR. Single cell responses to stimulation or inhibition of AC and PDE
isoforms were monitored with real-time cAMP probes. GLP-1 secretion was assessed by ELISA.
KEY RESULTS
Quantitative PCR identiﬁed expression of protein kinase C- and Ca2+-activated ACs, corresponding with phorbolester and
cytosolic Ca2+-stimulated cAMP elevation. Inhibition of PDE2, 3 and 4 were found to stimulate GLP-1 secretion from murine
L-cells in primary culture. This corresponded with cAMP elevations monitored with a plasma membrane targeted cAMP probe.
Inhibition of PDE3 but not PDE2 was further shown to prevent GLP-1 secretion in response to guanylin, a peptide secreted
into the gut lumen, which had not previously been implicated in L-cell secretion.
CONCLUSIONS AND IMPLICATIONS
Our results reveal several mechanisms shaping cAMP responses in GLP-1 secreting cells, with some of the molecular
components speciﬁcally expressed in L-cells when compared with their epithelial neighbours, thus opening new strategies for
targeting these cells therapeutically.
Abbreviations
AC, adenylate cyclase; cAMP, cyclic adenosine monophosphate; DPP-IV, dipeptidyl-peptidase IV; Epac2, cAMP-regulated
guanine nucleotide exchange factor II; FRET, Förster resonance energy transfer; fsk, forskolin; GIP, glucose-dependent
insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; PDE, phosphodiesterase
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Glucagon-like peptide 1 (GLP-1) is an incretin hormone
secreted from the intestinal L-cell after a meal. It potentiates
glucose-dependent insulin secretion from the pancreatic beta
cell, inhibits glucagon secretion from the pancreatic alpha cell
and reduces food intake (Drucker and Nauck, 2006; Holst,
2007;Gribble,2008).However,despiteitsproveneffectiveness
in people with type 2 diabetes, the peptide itself is unsuitable
as a therapeutic agent because it is rapidly inactivated by
dipeptidyl-peptidase IV (DPP-IV) (Drucker, 2007). This
problem has been overcome by a number of DPP-IV-resistant
mimetics with prolonged circulating half-lives, which are now
routinely used as subcutaneous injections for the treatment of
type 2 diabetes. DPP-IV inhibitors, by contrast, are orally
available, and act at least in part by increasing the half-life of
endogenously secreted GLP-1. As the plasma GLP-1 levels and
antidiabetic effects achieved by DPP-IV inhibition do not
match those of injectable mimetics (Nauck et al., 2009) an
obvious strategy would be to combine them with agents that
boost secretion of endogenous GLP-1. That such a GLP-1 pool
would be available and effective is suggested by the elevated
GLP-1 concentrations seen after bariatric surgery (Morínigo
et al., 2006; Dirksen et al., 2009; Vidal et al., 2009).
For such a strategy to be successful we need to understand
better what regulates the secretion of GLP-1 – and the
co-stored hormones oxyntomodulin, GLP-2 and peptide YY –
from enteroendocrine L-cells. Using model cell lines such as
STC-1 (derived from a murine small intestinal tumour), NCI-
H716 (derived from a poorly differentiated adenocarcinoma
of human caecum) and GLUTag (derived from a murine
colonic tumour), an elevation of intracellular cAMP has been
shown to be one of the strongest stimuli for GLP-1 secretion
(Katsuma et al., 2005; Simpson et al., 2007; Islam et al., 2009;
Lauffer et al., 2009). Downstream targets in cell lines have
been shown to include protein kinase A and cAMP-regulated
guanine nucleotide exchange factor II (Epac2) (Lotﬁ et al.,
2006; Simpson et al., 2007). cAMP levels reﬂect an equilib-
rium between production by adenylate cyclases and hydroly-
sis by phosphodiesterases. Both enzymes have a number of
isozymes and this study aimed to investigate which of these
are important in L-cell physiology.
Methods
Tissue culture
Colonic epithelial cells isolated from adult mice aged
between 6 to 20 weeks were cultured as described previously
(Reimann et al., 2008). All animal procedures were approved
by the local ethical committee and conformed to UK Home
Ofﬁce regulations. Brieﬂy, GLU-Venus transgenic mice were
killed by cervical dislocation and the gut collected into ice-
cold Leibovitz-15 (L-15) medium (PAA, UK). The colon was
dissected distal to the ileocolic junction, rinsed in L-15 and
minced. For culture, the tissue was digested three times with
Collagenase XI (0.4 mg·mL
-1) in Dulbecco’s modiﬁed Eagle’s
medium (DMEM, 25 mM glucose) for 10–15 min at 37°C.
Supernatants were centrifuged at 300¥ g and the pellets resus-
pended in DMEM supplemented with 10% FBS, 2 mM
L-glutamine, 100 U·mL
-1 penicillin and 0.1 mg·mL
-1 strepto-
mycin. Aliquots were plated onto 24-well plates coated with
Matrigel (BD Biosciences, Oxford, UK) for 24–36 h at 37°C,
5% CO2.
GLUTag cells were cultured in DMEM containing 5.5 mM
glucose supplemented with 10% FBS, 2 mM L-glutamine,
100 U·mL
-1 penicillin and 0.1 mg·mL
-1 streptomycin, as
described previously (Drucker et al., 1994; Reimann and
Gribble, 2002).
GLP-1 secretion
Cells were washed at least twice with standard bath solution
supplemented with 0.1% w·v
-1 bovine serum albumin (BSA,
fatty acid free). Experiments were performed by incubating
the cells with test reagents in the same solution for 2–4 h at
37°C. For primary cells, secreted and cellular GLP-1 were
extracted as previously described and quantiﬁed using an
ELISA speciﬁc for active GLP-1 (Millipore, Watford, UK)
(Reimann et al., 2008). Secretion was expressed as a fraction
of the total hormone (secreted + extracted) measured from a
well. For GLUTag cells only GLP-1 secreted into the superna-
tant was quantiﬁed. In both cases secretion was normalized
to the basal secretion measured under control conditions in
parallel in the same set of experiments.
cAMP measurements
GLUTag cells were transfected with 3 mg of the Förster reso-
nance energy transfer (FRET) cAMP probes, Epac1-camps,
Epac2-camps, or pmEpac2-camps using Lipofectamine 2000
reagent (Invitrogen, Paisley, UK), overnight. The cells were
then seeded onto matrigel-coated glass dishes (MatTek,
Ashland, MA, USA) and imaged 24–96 h later. Apart from
initial experiments [contributing to Figure 2 and performed
in Dermot Cooper’s laboratory using equipment described
elsewhere (Goraya et al., 2008)], experiments were performed
using an inverted ﬂuorescence microscope (Olympus IX71,
Southall, UK) with a 40¥ oil-immersion objective. The FRET
probe was excited every 2–5 s at 435/10 nm using a 75 W
xenon arc lamp and a monochromator (Cairn Research,
Faversham, UK) controlled by MetaFluor software (Molecular
Devices, UK). Emission was recorded with an Orca-ER CCD
camera (Hamamatsu, Welwyn Garden City, UK) behind an
Optosplit II image splitter (Cairn Research) equipped with
cyan ﬂuorescent protein (CFP) and yellow ﬂuorescent protein
(YFP) emission ﬁlter sets, acquiring 470/24 nm and 535/
30 nm respectively. Fluorescence was recorded from indi-
vidual cells and background corrected and expressed as the
ratio of CFP over YFP. For illustrations traces were smooth-
ened using adjacent averaging over 5 points in origin.
In some experiments three-cube measurements were used
in order to correct for bleed through signals and non-speciﬁc
excitation of the two ﬂuorophores (Gordon et al., 1998; Chen
et al., 2006). Cells were excited at 435/10 nm for 250 ms and
500/10 nm for 40 ms every 2–5 s. Direct YFP excitation and
bleed through of CFP emission into the YFP channel were
corrected for after calculation of the setup parameters a =
Ida/Iaa and d = Ida/Idd in which Ida is the observed emission from
the acceptor (YFP) upon excitation of the donor (CFP), Iaa is
the observed emission of the acceptor upon excitation with
an acceptor-speciﬁc wavelength (500/10 nm) and Idd is the
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wavelength (435/10 nm). We measured values of a = 0.134 
0.001 and d = 0.776  0.015 using GLUTag cells transfected
with YFP and CFP probes individually, allowing the calcula-
tion of corrected FRET signals (Fc) with the formula Fc = Ida -
aIaa - dIdd.
Reagents were prepared in standard saline and perfused at
~1 mL·min
-1. At the end of each experiment, cAMP was maxi-
mally elevated by co-application of 10 mM forskolin (forsko-
lin) and 100 mM 3-isobutyl 1-methylxanthine (IBMX)
(forskolin/IBMX). Average ﬂuorescence readings in individual
cells were determined over ~40 s before and at the peak of the
response. Peak FRET responses were obtained by subtraction
of the baseline from the averaged peak response. All test
responses are expressed relative to the maximal response
(forskolin/IBMX) in that individual cell. For experiments
with different PDE inhibitors cells were primed with a pre-
application of forskolin. This protocol was developed after
initial attempts, in which cells were treated with PDE inhibi-
tors alone, elicited only small or undetectable and variable
cAMP responses, presumably due to low or ﬂuctuating basal
AC and PDE activity. IBMX response size was not reproduc-
ible after forskolin priming, in contrast to the response to a
cocktail mix of PDE-2,3 and 4 inhibitors. Individual inhibitor
responses are thus reported as a fraction of the response to a
cocktail mix of all three PDE inhibitors investigated, which
was applied randomly either before or after the individual
test inhibitor.
Ca
2+-measurements
In some experiments cytosolic Ca
2+ and cAMP concentrations
were monitored simultaneously after loading the cells with
the AM-ester of the Ca
2+-sensitive dye Fura-2, as previously
described (Reimann et al., 2004). Brieﬂy, cells were addition-
ally excited at 340/10 nm and 380/4 nm for 250 ms every 5 s
and 340/380 ratios were calculated from background sub-
tracted emissions measured in the YFP channel. Cells were
pooled into Ca
2+-responsive cells and Ca
2+-unresponsive cells
determined by a change of the 340/380 nm signal of 0.05
and <0.05 (relative to basal readings) in response to 30 mM
KCl respectively.
Expression analysis by quantitative PCR
RNA was extracted from GLUTag cells using TRI reagent and
reversed transcribed as described previously (Reimann and
Gribble, 2002). For primary tissue, cells were isolated from
transgenic mice expressing the ﬂuorescent protein Venus
under the control of the proglucagon promoter (Reimann
et al., 2008). Colonic tissue was digested to single cells with
collagenase and sorted into Venus-ﬂuorescent positive L-cells
and non-ﬂuorescent control cells using a MoFlo Beckmann
Coulter Cytomation sorter. RNA was isolated from ~10 000
cells sorted into lysis buffer using micro scale RNA isolation
kit (Ambion/Applied Biosystems, Warrington, UK) and
reverse transcribed according to the manufacturer’s instruc-
tions (SuperScriptII, Invitrogen). cDNA from 3 independent
RNA isolations/FACS sorts was ampliﬁed with QuantiTect
SYBR Green PCR mix (Qiagen) or Absolute Blue SYBR Green
ROX mix (ABgene/Thermo Fisher Scientiﬁc, Epsom, UK)
using speciﬁc primers designed with Primer-BLAST (NCBI)
software (see Table 1) on an Applied Biosystems 7900 HT Fast
real-time PCR system controlled by SDS 2.3 software. In all
cases, expression was compared with that of b-actin measured
on the same sample in parallel on the same plate, giving a CT
Figure 1
GLP-1 secretion in response to AC-activation. (A, B) Dose-dependent stimulation of GLP-1 secretion from (A) murine colonic epithelial cultures and
(B) GLUTag cells incubated with bath solution containing the forskolin concentration indicated. Secreted GLP-1 is expressed relative to the
amounts secreted in the absence of forskolin on the same day. Each point represents results from 3–6 wells and error bars represent 1 SEM. The
solid line dose–response curves were ﬁtted to the data set using a logistic equation, giving EC50so f1 . 9 1.7 mM( A )a n d1 . 5 0.4 mM( B )
respectively. (C) GLP-1 secretion from murine colonic epithelial cultures incubated with either 10 or 100 nM PACAP as indicated. Secretion was
normalized to secretion measured in parallel in the absence of PACAP (indicated by the dashed line). The number of wells is indicated above the
bars and error bars represent 1 SEM. Statistical signiﬁcance comparing to basal secretion in the absence of PACAP was evaluated using Student’s
one-factor t-test. **P < 0.01; *P < 0.05.
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Oligonucleotides used for RT-PCR
A
AC
NCBI mRNA
accession No.
Amplicon length (region
of mRNA ampliﬁed) Primer Sequences (5-3)
AC1 NM_009622 102 (606–707) F: CCTTTTGGTCACCTTCGTGT
R: GCTGTGACCAGTAAGTGCGA
AC2 NM_153534 126 (2044–2169) F: GCACTGCCAGCATTCAAGTA
R: GAGAAATGCAGCTCCAAAGG
AC3 NM_138305 120 (1028–1147) F: ATGAAGAAGGACGAGAGCCA
R: AGCAGAGGACAGCTGGGTAA
AC4 NM_080435 170 (1613–1782) F: GTGTCCACCTCCACTCCACT
R: AAGTCCTTCGACTGCTTCCA
AC5 NM_001012765 106 (3816–3921) F: GGCAGCTGGAAAAGATCAAG
R: GCAATAGCCTTGATGTGGGT
AC6 NM_007405 172 (2255–2426) F: TATGCCGCTATCTTCCTGCT
R: TGGCAGAGATGAACACAAGC
AC7a NM_007406 143 (2415–2557) F: AAGGGCTTTGAGCGTGAGTA
R: CCAAAGGACACACCCAGAGT
AC8 NM_009623 113 (1600–1712) F: TCGGATTTCTTCCTCAATGG
R: CCCAGGAAATAGCGTTGGTA
AC9 NM_009624 131 (3875–3967) F: CGGTCTCCCACAGATGAGAT
R: GGCTCTCTCCAGGACCTCTT
sAC (AC10) NM_173029 154 (1833–1986) F: GGCTGTTGCTATTGCACTGA
R: CTCATCCAACAGCGTCTTGA
B
PDE
NCBI mRNA
accession No.a
Amplicon length (region
of mRNA ampliﬁed) Primer Sequences (5-3)
Transcript
variants
detected
1a NM_001159582 147 (1066–1212) F: CACTGGCTCACTGAACTGGA 1, 2, 7, 9
R: ATTCTCAAGCACTGAGCGGT
1b NM_008800 126 (1303–1428) F: TGCCCTTCTCTCCACTCTGT N/A
R: GCTGGACACTCTTTTCTGCC
1c NM_011054 102 (1885–1986) F: TTGACGAAAGCTCCCAGACT 1, 2, 3, 4, 5, 6, 7, 8
R: ACCCAGAACTCTTGACACCG
2a NM_001143848 124 (651–774) F: CAAGTGCTGGTCATACCCCT 1, 2, 3, 4
R: GAGCGTGCTTCTCTACCACC
3a NM_018779 128 (2438–2565) F: AATGTGGCCGTATTCTGAGC N/A
R: GTCCCTGTATCCGATCTCCA
3b NM_011055 105 (1178–1282) F: GACCGTCGTTGCCTTGTATT N/A
R: CTCCATTTCCACCTCCAGAA
4a NM_019798 115 (513–627) F: GGAAATGAGCAGGTCAGGAA 1, 5
R: CTGCTGGAAGGGTCTCTGTC
4b NM_019840 144 (1187–1330) F: GCTCAAGCCTGAACAACACA N/A
R: TAAGGGGCCGATTATGTGAG
4c NM_201607 138 (1169–1306) F: TGTTCAAAGTGGCTGAGCTG N/A
R: GCCCCTCTAGTGTCAGCAAG
4d NM_011056 137 (1101–1237) F: GAAGTTGATGCACAGCTCCA N/A
R: GCTCTGCTATTCGGAAAACG
7a NM_008802 146 (781–926) F: CCAGGTGTTAATCAGCCGTT 1, 2
R: TCCAATGGCAAGTGTGAGAA
7b NM_013875 116 (490–605) F: CCATGCATCTAGGCTTCTCC N/A
R: CAAAGTCCCACGTTCCAACT
8a NM_008803 139 (275–413) F: GCGCCTCGAAGGTATCAGTA N/A
R: AACCCAGCTTTCTCACATGC
8b NM_172263 143 (1102–1244) F: GTAGCAGAGGCCTTGGACAG N/A
R: CCTGACAGTCTCCTCAAGCC
10a NM_011866 114 (2231–2344) F: ACCGACCTCGCCCTATACTT N/A
R: CATCATCAAGCCGATGACAC
11a NM_001081033 142 (1374–1515) F: AACTGATGTCCCCAAAGTGC N/A
R: TCGCTGACATTCACAGGAAG
(A) Primer sequences for known AC isoforms in Mus musculus. aPrimers for AC7 are not transcript-variant speciﬁc. Primers amplify all four transcript variants. Accession number given is for
transcript variant 1.
(B) Primer sequences for known cAMP-PDE families in Mus musculus. In all cases, primers were designed to amplify every transcript variant catalogued on NCBI. aNon-speciﬁc to transcript
variants, accession number refers to variant 1.
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b-actin ranged from 20–25 in the different samples, and reac-
tions in which the test gene was undetectable were assigned
aC T value of 40. A DCT value of -12 to -15 is therefore close
to the detection limit of the assay. Mean, standard error and
statistics were performed on the DCT data and only converted
to relative expression levels (2
∧DCT) for presentation in the
ﬁgures.
Solutions
The standard bath solution used for most experiments con-
tained (in mM): 4.5 KCl, 138 NaCl, 4.2 NaHCO3, 1.2
NaH2PO4, 2.6 CaCl2, 1.2 MgCl2, and 10 HEPES (pH 7.4,
NaOH). Calcium-free buffer was a modiﬁed bath solution in
which CaCl2 was omitted and 0.5 mM EGTA was included.
For experiments in which cells were depolarized by elevation
of the extracellular potassium concentration to 30 mM, NaCl
was concomitantly reduced to 112.5 mM to maintain osmo-
larity. Where possible all drugs were prepared as a 1000X
stock. All reagents were supplied by Sigma (Poole, UK) unless
otherwise stated.
Analysis
Comparisons between conditions were made using regression
analysis or by Student’s two sample or one sample t-tests
(Microsoft Excel), as indicated, with a threshold for signiﬁ-
cance of P = 0.05. The dose–response curves in Figures 1 and
2 were ﬁt with a logistic equation y = A2 + ((A1-A2)/(1 +
([fsk]/EC50)^p)) using Microcal Origin software. All data are
expressed as mean  SEM.
Results
To investigate if activation of adenylate cyclase is sufﬁcient to
stimulate GLP-1 secretion we incubated GLUTag cells and
Figure 2
Changes in cAMP concentration in response to AC-activation. (A) GLUTag cells transfected with cytosolic Epac1-based FRET probes were perfused
with 1 mM (left) or 3 mM (right) forskolin, followed by 10 mM forskolin/100 mM IBMX, as indicated while CFP and YFP emission was monitored in
response to excitation with 435/10 nm. Each trace represents the CFP/YFP ratio of a single cell normalized to the starting value. (B) Changes in
the CFP/YFP emission ratio in response to forskolin concentrations ranging from 100 nM to 30 mM for cells transfected with (left) Epac1-camps
or (right) Epac2-camps. Each point represents measurements of a single cell; n = 18–40 from 4 separate experiments for each concentration.
Data are presented as signal change in response to forskolin expressed as a fraction of the maximal CFP/YFP rise, achieved using 10 mM
forskolin/100 mM IBMX at the end of the experiment as seen in (A). Logistic curves were ﬁt and EC50s were 3.4  0.6 mM for Epac1-camps and
3.4  0.9 mM for Epac2-camps. (C) Changes in the CFP/YFP emission ratio in response to saline control, PACAP (100 nM) or GIP (100 nM) as
indicated. Each treatment was applied to n = 22–28 cells in 4 separate experiments and responses were normalized to the maximal response
elicited by 10 mM forskolin/100 mM IBMX. Statistical signiﬁcance was assessed using Student’s unpaired t-test; ***P < 0.001, as compared with
control. Error bars represent 1 SEM.
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Secretion was triggered dose-dependently by forskolin, with
EC50so f1 . 9 1.7 mM and 1.5  0.4 mM respectively
(Figure 1A,B). GLP-1 secretion from primary L-cells was also
stimulated by application of pituitary adenylate cyclase acti-
vating peptide (PACAP) (Figure 1C).
To monitor changes in intracellular cAMP in response to
these agents in single cells, we transfected GLUTag cells with
FRET-based cAMP sensors Epac1-camps and Epac2-camps
(Nikolaev et al., 2004). With these probes, cAMP elevation
results in an increase of the CFP/YFP emission ratio on exci-
tation at 435 nm. As shown in Figure 2A, the CFP/YFP ratio
increased in single cells within seconds of applying forskolin.
Incubation with saturating concentrations of forskolin
(10 mM) and IBMX (100 mM) (Ong et al., 2009) at the end of
the experiment was used to evaluate the maximal response. A
dose–response curve was constructed for forskolin using the
two different probes (Figure 2B), and showed that the pattern
of cAMP changes mirrors the pattern of GLP-1 secretion,
with both probes showing an EC50 for forskolin of 3.4 mM.
We also observed changes in FRET when we applied PACAP
or glucose-dependent insulinotropic polypeptide (GIP)
(Figure 2C). The responses were generally slow to reverse, and
were each ~30% of the maximal response to forskolin/IBMX.
To identify members of the adenylate cyclase families that
might play a role in mediating the effect of Gs-coupled recep-
tors, we examined expression levels of the different gene
families by quantitative RT-PCR in GLUTag cells, primary
colonic L-cells and non-ﬂuorescent control colonic cells
(Figure 3). L-cells expressed relatively high mRNA levels of
AC2, 5, 6, 8 and 9. AC6 was the most abundantly detected
adenylate cyclase mRNA in all three cell populations and no
signiﬁcant differences in expression levels were detected
between L-cells and their non-ﬂuorescent neighbours, an
observation also true for AC9. mRNA for the calcium-
sensitive AC1 was highly expressed in GLUTag cells, but not
in primary L-cells, which, however appeared to express
higher levels of another Ca
2+-sensitive adenylate cyclase, AC8.
AC5, the mRNA for which was expressed at similar levels in
both primary cell populations, was absent from the GLUTag
cell line. Of all the AC mRNAs expressed in L-cells, only AC2
was expressed at signiﬁcantly higher levels in L-cells com-
pared with their neighbours, and the expression level of this
enzyme seemed preserved in the GLUTag cell line.
AC2 has previously been implicated in crosstalk between
protein kinase C (PKC)-activation and cAMP-signalling (Jaco-
bowitz and Iyengar, 1994). We therefore tested the effects of
the phorbol ester, phorbol 12-myristate 13-acetate, on single
cell cAMP levels and found signiﬁcant increases in the FRET
signal of Epac2-camps-transfected GLUTag cells (Figure 4A).
Another important stimulus for GLP-1 secretion is the eleva-
tion of cytosolic Ca
2+, which could potentially elevate cAMP
levels via the Ca
2+-sensitive cyclases AC1 (in GLUTag cells)
and AC8 (in L-cells). Using 30 mM KCl to depolarize GLUTag
cells and open voltage-gated Ca
2+ channels, we observed
a strong correlation between elevations of cytosolic Ca
2+
monitored by Fura2 and cAMP monitored by Epac2-camps
(Figure 4B,C). This was further explored in experiments
applying 30 mM KCl in the absence of extracellular Ca
2+.
Under these conditions KCl failed to trigger fura-2 340/380-
ratio changes (not shown), and Epac-2-camps FRET changes
were signiﬁcantly smaller compared with the changes
observed in the same cells stimulated by KCl in the presence
of Ca
2+ in the bath solution (Figure 4D).
Although Gas stimulation usually raises cAMP levels
by coupling to adenylate cyclases, inhibition of cAMP-
phosphodiesterase activity may also result in increased cyto-
solic cAMP. We previously reported microarray expression
data of PDE-isoforms in L-cells (Ong et al., 2009). This was
further quantiﬁed by RT-PCR, conﬁrming signiﬁcant mRNA
expression of PDE2a, 3b, 4d, 7a, 8a and 8b in primary L-cells
(Figure 5). However, by using RT-PCR we also detected signiﬁ-
cant levels of mRNA for PDEs 1c, 3a and 11a, but did not
conﬁrm the intermediate levels detected by microarray for
PDEs 1b and 10a. PDE2a, 4d, 8a, 8b and 11a mRNAs were
expressed at signiﬁcantly higher levels in L-cells compared
with their neighbouring non-L-cells, and their expression was
broadly similar in primary L-cells and GLUTag cells.
We next examined whether speciﬁc inhibition of PDE-2, 3
or 4, using BAY-60-7550, Org-9935 and rolipram, respectively,
affected GLP-1 secretion from primary colonic cultures.
GLP-1 secretion was enhanced similarly by BAY-60-7550, Org
9935 and rolipram, although all agents were less effective
than the non-selective PDE inhibitor, IBMX (Figure 6A).
Using the global Epac2-camps probe in GLUTag cells, we
observed that rolipram, but not Org-9935 or BAY-60-7550,
triggered signiﬁcant changes in the FRET signal, indicating a
rise in the cytosolic cAMP concentration (Figure 6B,C). In
view of the ﬁnding that all three PDE inhibitors stimulated
GLP-1 secretion from primary colonic cultures, we repeated
the cAMP imaging experiment using a FRET probe targeted to
the plasma membrane through an N-terminal modiﬁcation
Figure 3
Expression of adenylate cyclases in colonic L-cells. Histogram
showing the relative mRNA expression of adenylate cyclase genes in
colonic Venus-ﬂuorescence-negative (non-L-cells), ﬂuorescence-
positive (L-cells) and GLUTag cells. Expression was analysed by quan-
titative RT-PCR and compared with that of b-actin in the same
sample; 3–6 samples from separate mice were analysed for each
column. Data are presented as geometric mean, and the error bar
was calculated from the log(base 2) data representing the upper
SEM. Signiﬁcance comparisons for each AC were performed ﬁrst by
ANOVA [which showed signiﬁcant differences between the three cell
types for all ACs, except AC8, AC9 and soluble AC (sAC)], and
subsequently by comparing only non-L-cells and L-cells by Student’s
unpaired t-test; *P < 0.05; **P < 0.01.
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initiates palmitoylation and myristoylation at the cysteine
and glycine residues respectively (pmEpac2-camps; Wachten
et al., 2010). Interestingly, cAMP at the plasma membrane
was signiﬁcantly enhanced by all three PDE inhibitors, more
closely mirroring the ﬁndings in secretion experiments
(Figure 6D).
Interestingly, two of the PDEs found in L-cells are known
to be additionally modulated by cGMP. Thus, PDE2 is allos-
terically activated by cGMP, and PDE3 is competitively inhib-
ited. We therefore tested if and how these PDEs might be
involved in crosstalk between cAMP and cGMP signalling in
L-cells. We found primary L-cells to express relatively high
levels of mRNA for the guanylate cyclase-coupled receptor
Figure 4
Phorbol-ester and Ca
2+-stimulated changes in cAMP concentration. (A) (left) cAMP level monitored as ratio of CFP to corrected FRET (Fc) in GLUTag
cells transfected with Epac2-camps and excited at 435/10 nm and 500/10 nm. Traces represent individual cell responses. Cells were treated with
PMA (1 mM) and forskolin/IBMX (10 and 100 mM, respectively) as indicated. (right) Mean responses as measured on the left expressed as a fraction
of the maximal response elicited by forskolin/IBMX. Each treatment was applied to n = 15–18 cells in 3 separate experiments. ***P < 0.001 as
compared with vehicle control. Statistical signiﬁcance was assessed by Student’s unpaired t-test and error bars represent 1 SEM. (B) (left) cAMP
concentration (top) and [Ca
2+] (bottom) monitored as ratio of CFP to corrected FRET (Fc) and 340/380 nm emission ratio, respectively, in GLUTag
cells transfected with Epac2-camps and loaded with Fura-2 and excited at 435/10 nm, 500/10 nm, 340/8 nm and 380/4 nm. The blue trace
represents a Ca
2+-responsive and the red trace a Ca2+-unresponsive cell monitored simultaneously in the same experiment. Top and bottom plots
are from the same experiment. KCl (30 mM) and forskolin/IBMX (10 and 100 mM, respectively) were applied as indicated. (C) Mean cAMP
responses to 30 mM KCl or saline relative to the maximal responses, as elicited using 10 mM forskolin/100 mM IBMX. Cells were pooled into
Ca
2+-responsive cells (increase in 340 nm/380 nm signal of 0.05 in response to 30 mM KCl) and Ca2+-unresponsive cells (increase in 340 nm/
380 nm signal of <0.05 in response to 30 mM KCl). Each treatment was for n = 4-22 cells in 3 separate experiments. Statistical signiﬁcance was
assessed by Student’s unpaired t-test and error bars represent 1 SEM.*P < 0.05 as compared with Ca
2+-unresponsive cells; +++P < 0.001 as
compared with saline control. (D) Mean cAMP responses to 30 mM KCl relative to the maximal responses, as elicited using 10 mM forskolin/
100 mM IBMX in the presence and absence of extracellular Ca
2+. Only cells showing a KCl induced Ca
2+-response of 0.05 in the presence of
extracellular Ca2+ were included in the analysis (n = 4 excluded on this basis). Data represent n = 11 cells in four separate experiments. Statistical
signiﬁcance was assessed by Student’s paired t-test and error bars represent 1 SEM.*P < 0.05 as compared with Ca
2+-free condition.
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hybridization data, not shown). Application of 1 mM guany-
lin stimulated GLP-1 secretion from primary L-cells and this
effect was blocked when cultures were pretreated with 10 mM
IBMX or the PDE3-speciﬁc inhibitor Org-9935 (10 mM)
(Figure 7). By contrast, inhibition of PDE2, which can be
allosterically activated by cGMP, did not prevent guanylin-
stimulated GLP-1 secretion (Figure 7).
Discussion and conclusions
Elevation of cAMP is perhaps the most effective stimulus for
GLP-1 secretion from L-cells identiﬁed to date. Similar to our
observation with the model L-cell line GLUTag (Simpson
et al., 2007), we found previously that direct activation of
adenylate cyclase and concomitant inhibition of phosphodi-
esterase using forskolin and IBMX respectively, provided a
strong stimulus for secretion from murine L-cells in primary
culture, potentiating both basal and glucose-stimulated secre-
tion (Reimann et al., 2008). While activation of adenylate
cyclase – for example, in response to GIP or PACAP (Brubaker
et al., 1998; Simpson et al., 2007) – is sufﬁcient to stimulate
GLP-1 release in the absence of pharmacological phosphodi-
esterase inhibition, previously, we were technically limited to
monitoring total intracellular cAMP changes in GLUTag cells
at a ﬁxed time point after Gas-stimulation and in the con-
comitant presence of the broad-spectrum PDE inhibitor
IBMX (Simpson et al., 2007). Utilizing ﬂuorescent FRET-based
sensors, we now demonstrate dynamic single cell monitoring
of cAMP changes. With these probes, we found that cAMP
responses to a variety of stimuli, including stimulation of the
Gas-coupled GIP and PACAP receptors, were reproducible
without the need for PDE inhibition and could be normalized
to maximal FRET responses triggered by forskolin plus IBMX
in the same cells at the end of the experiment. Using this
protocol we obtained forskolin dose–response curves with
two slightly different FRET sensors based on Epac2 and Epac1
respectively. No signiﬁcant difference in sensitivity between
the probes was observed and the estimated EC50 for forskolin
closely matched its potency to trigger GLP-1 secretion from
both GLUTag cells and murine L-cells in primary culture.
cAMP levels are dynamically regulated as a result of
changes in the activities of cAMP-producing enzymes (ACs)
and cAMP-hydrolysing enzymes (PDEs). We used our recently
established transgenic mouse with ﬂuorescently labelled
L-cells (see Reimann et al., 2008) to investigate the mRNA
expression of ACs and PDEs in these cells and their
non-ﬂuorescent neighbours, a population dominated by
enterocytes.
All membrane-bound ACs are stimulated by Gas and for-
skolin, but can be further grouped based on their sensitivity
to other stimuli; thus AC1, AC3 and AC8 are activated while
AC5 and AC6 are inhibited by Ca
2+/calmodulin and AC2, AC4
and AC7 are activated by PKC phosphorylation or Gbg sub-
units (Hanoune et al., 1997; Patel et al., 2001). Of the ACs
only AC2 mRNA was speciﬁcally enriched in the enteroendo-
crine cells and these higher expression levels were preserved
in the immortalized L-model cell line GLUTag. Consistent
with reports of AC2 being stimulated by PKC phosphoryla-
tion (Jacobowitz and Iyengar, 1994; Cooper et al., 1995), we
observed elevations of cytosolic cAMP levels in response to
phorbol ester application. Potential crosstalk with cAMP-
dependent pathways should therefore be taken into account
when signals from Gaq-coupled receptors, such as GPR40 and
GPR120, which have been implicated in fatty acid stimulated
GLP-1 secretion, are investigated. The situation is further
complicated by the ﬁnding that elevated Ca
2+ itself was a
strong stimulus for cAMP elevation in GLUTag cells, presum-
ably via AC1 activation. Although primary L-cells appear to
express less AC1 mRNA than GLUTag cells, they have corre-
spondingly higher mRNA expression levels of an alternative
Figure 5
Expression of cAMP-phosphodiesterases in colonic L-cells. Histogram showing the relative mRNA expression of cAMP-hydrolysing phosphodi-
esterase genes in colonic Venus-ﬂuorescence-negative (non-L-cells), ﬂuorescence-positive (L-cells) and GLUTag cells. Expression was analysed by
quantitative RT-PCR and compared with that of b-actin in the same sample; 3–6 samples from separate mice were analysed for each column. Data
are presented as geometric mean, and the error bar was calculated from the log(base 2) data representing the upper SEM. Signiﬁcance
comparisons for each PDE were performed ﬁrst by ANOVA (which showed signiﬁcant differences between the 3 cell types for all PDEs), and
subsequently by comparing only non-L-cells and L-cells by Student’s unpaired t-test; *P < 0.05; **P < 0.01; ***P < 0.001.
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2+-stimulated cyclase, AC8. While we observed a strong
correlation between KCl triggered Ca
2+ and cAMP elevation,
some small additional Ca
2+-independent effect of KCl on
cAMP levels was also observed when extracellular Ca
2+ was
removed. As we previously showed that forskolin/IBMX
application can promote Ca
2+ increases in GLUTag cells
as a consequence of modulatory effects on ion-channel
activity (Reimann et al., 2005; Simpson et al., 2007), it will be
Figure 6
Effects of phosphodiesterase inhibition. (A) GLP-1 secretion from murine colonic epithelial cultures incubated for 2 h with either IBMX (100 mM),
BAY-60-7550 (50 and 300 nM), rolipram (10 mM) and Org 9935 (10 mM) or control in bath solution supplemented with 10 mM glucose. Secreted
GLP-1 was normalized to the total content of each well and data were further normalized to the GLP-1 secretion measured in the absence of PDE
inhibition on the same day (control, dashed line). The number of wells is shown above the columns. Signiﬁcance comparisons were performed
ﬁrst by ANOVA (which showed signiﬁcant differences between groups), and subsequently by comparing each PDE inhibitor to control by Student’s
t-tests; ***P < 0.001;*P < 0.05; error bars represent 1SEM. (B) Example trace of cAMP concentration as monitored by changes in CFP/Fc.A f t e ra n
initial priming with forskolin (10 mM) Epac2-camps-transfected GLUTag cells were perfused with a cocktail of three PDE inhibitors [rolipram
(10 mM) + BAY-60-7550 (50 nM) + Org 9935 (10 mM)] or rolipram (10 mM) alone as indicated. Traces represent single cells normalized to a range
between 0 and 1 for clarity. (C) Rises in cAMP concentration as monitored with Epac2-camps in response to speciﬁc PDE2, 3 and 4 inhibitors,
expressed as fractions of the cAMP response to the cocktail of these inhibitors either applied before (as shown in B) or after the application of the
single agent, DMSO (0.1%; vehicle control), BAY-60-7550 (50 nM), rolipram (10 mM) and Org 9935 (10 mM). Single cell measurements from
n = 13–25 cells were included for each treatment from 4 separate experiments per treatment. Numbers of cells included in the analysis are given
above each column before the slash. Numbers after the slash indicate the total number of cells measured. The difference is made up of cells
excluded on the basis that they did not respond to the inhibitor cocktail with CFP/Fc changes 5%. Statistical signiﬁcance as compared with the
vehicle control (DMSO, 0.1%) was evaluated using Student’s t-test. **P < 0.01, after initial assessment by ANOVA had indicated signiﬁcant
differences between groups. (D) As in (C) but monitored with the plasma membrane targeted probe pmEpac2-camps. Single cell measurements
from n = 8–16 cells were included for each treatment from 4 separate experiments per treatment. Statistical signiﬁcance as compared with the
vehicle control (DMSO, 0.1%) was evaluated using Student’s t-test. ***P < 0.001; **P < 0.01, after initial assessment by ANOVA had indicated
signiﬁcant differences between groups.
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changes in Ca
2+, cAMP and electrical activity.
While there is a scarcity of pharmacological tools with
speciﬁcity for members of the adenylate cyclase family, such
tools are available for the cAMP-hydrolysing phosphodi-
esterases. By RT-PCR we detected a qualitatively similar PDE
mRNA expression proﬁle for L-cells to that found previously
by microarray analysis. PDE2a and PDE4d seemed to be the
predominant isoforms speciﬁcally expressed in L-cells, with
moderate but detectable levels of PDE1c, PDE3a, PDE8a,
PDE8b and PDE11a mRNAs. Consistent with previous reports
showing acute GLP-1 responses in rats upon injection of the
PDE4 inhibitor rolipram (Ong et al., 2009), we observed an
elevation of cAMP in GLUTag cells when rolipram was
applied, presumably due to inhibition of PDE4d. The fact that
we did not observe similar changes in response to the PDE2
and PDE3 inhibitors Bay-60-7550 and Org 9935 using the
‘cytosolic’ FRET sensor probably reﬂects compartmentaliza-
tion of different PDEs within the cell. Different PDEs, includ-
ing PDE2-, PDE3- and PDE4-family isoforms, have been
shown to be targeted to speciﬁc subcompartments either
close to cAMP-production or -sensing sites, with further
speciﬁcity achieved through alternative splicing (Shakur
et al., 2000; Mongillo et al., 2006; Nilsson et al., 2006;
Houslay, 2010). However, the observed stimulation of GLP-1
secretion by rolipram, Bay-60-7550 and Org 9935, corre-
sponds well with the cAMP changes seen in response to all
three agents when monitored with a plasma membrane tar-
geted sensor, thus suggesting a role for PDE2a, PDE3a/b and
PDE4d in GLP-1 secretion, even if the cAMP concentration at
the site of the non-targeted ‘cytosolic’ FRET sensor is domi-
nated by PDE4-activity.
In contrast to PDE4, which is cAMP-speciﬁc, PDE2 and
PDE3 can both also hydrolyse cGMP. They differ, however, in
their sensitivity to cGMP, which allosterically activates PDE2
but competitively inhibits PDE3. Our observation that acti-
vation of the guanylate cyclase-coupled guanylin receptor
(GC-C) stimulates GPL-1 secretion suggests a stimulating role
for cGMP, acting either via PDE3 inhibition or an alternative
signalling pathway. The idea that it acts through PDE3 is
suggested by the ﬁnding that guanylin was ineffective on
GLP-1 secretion in the presence of the non-speciﬁc PDE
inhibitor IBMX or the PDE3-speciﬁc inhibitor Org 9935,
whereas its effect was retained, or even tended to increase,
when PDE2 was inhibited by Bay-60-7550. Guanylin is
believed to be secreted into the lumen of the intestine (Currie
et al., 1992; de Sauvage et al., 1992) and our results suggest it
may stimulate more distally located L-cells via a GC-C recep-
tor pathway resulting in cGMP elevation and inhibition of
PDE3. Stimulation of GLP-1 release by guanylin has not pre-
viously been reported and may represent a novel paracrine
signalling loop within the intestine.
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